G. Sweeney et al., CONTRACTILE RESPONSES TO SUMATRIPTAN IN ISOLATED BOVINE PULMONARY-ARTERY RINGS - RELATIONSHIP TO TONE AND CYCLIC-NUCLEOTIDE LEVELS, Journal of cardiovascular pharmacology, 26(5), 1995, pp. 751-760
We examined responses to the 5-hydroxytryptamine(1D) (5-HT1D)-receptor
agonist sumatriptan in bovine pulmonary artery rings (2-3 mm ID). The
effects of agonist-induced tone and agents that alter intracellular c
yclic AMP [cyclic AMP](i) or [cyclic GMP](i) on responses to sumatript
an were investigated, At resting tension, responses to sumatriptan wer
e slight or not evident. In the presence of tone induced by U46619, re
sponses to sumatriptan (1 nM-30 mM) were greatly potentiated, as were
responses to the alpha(2)-adrenoceptor agonist UK14304, Responses to t
he alpha(1)-adrenoceptor agonist phenylephrine (PE) were potentiated o
nly slightly. In the presence of U46619, addition of the adenylyl cycl
ase activator, forskolin (1 nM-0.1 mu M) or isoprenaline (ISO 1 mu M)
induced relaxations and increases in [cyclic AMP](i) and resulted in f
urther potentiation of the contractile response to sumatriptan. Additi
on of 0.1 mu M sodium nitroprusside (SNP) inhibited sumatriptan-induce
d contractions, Whereas sumatriptan alone did not significantly affect
[cyclic AMP](i), in the presence of U46619 it decreased [cyclic AMP](
i). This effect of sumatriptan was further enhanced in the presence of
forskolin. Sumatriptan increased [cyclic GMP](i). Using a nitric oxid
e (NO) synthase inhibitor and vessels denuded of endothelium, we showe
d that the increased [cyclic GMP](i) in response to sumatriptan was en
dothelium-dependent and mediated by NO. This increase in [cyclic GMP](
i) was not observed in the presence of U46619. By measuring cyclic AMP
and cyclic GMP phosphodiesterase (PDE) levels, we demonstrated that t
he point of ''cross-talk'' between cyclic nucleotides may not be at th
e level of total PDE activity. These results highlight the important r
ole of [cyclic AMP](i), [cyclic GMP](i), and endothelium function in t
he control of 5-HT1D receptor-mediated vasoconstriction, which is depe
ndent on a decrease in [cyclic AMP](i) in the absence of an increase i
n [cyclic GMP](i).